| Document Date: 2015-03-23 14:07:33
Open Document File Size: 170,31 KBShare Result on Facebook
Company Haemophilia Reference / FVIII / Haemophilia Registry / Plain Language Summary / Haemophilia First / Governance / / Country United Kingdom / / Currency GBP / / IndustryTerm rituximab biosimilar products / literature search / healthcare / / MedicalCondition inherited disorder / acquired haemophilia A / autoimmune disorders / allergic reaction / adult acquired haemophilia A / disease / haematological diseases / haemophilia / neutropenia / cardiovascular disease / diabetes / European Acquired Haemophilia / acquired hemophilia A / congenital haemophilia A / rheumatological diseases / acquired haemophilia / infection / specialised haemophilia / disorders / / MedicalTreatment immunosuppression / Immunosuppressive therapies / invasive procedures / surgery / / Organization NHS / / Product prednisolone / cyclophosphamide / Azathioprine / / PublishedMedium The Franchini review / / Technology antibodies / /
SocialTag |
Clinical Commissioning Policy: The use of Rituximab as a second line agent for the eradication of inhibitors in patients with Acquired Haemophilia Reference: NHS England xxx/x/x 1